OneSource Specialty Pharma Limited has announced a major milestone in its global pharmaceutical business after supporting the approval of the second generic semaglutide injection in Canada.

The company informed stock exchanges on May 04, 2026, that its partner Orbicular, along with its Canadian front-end partner, received approval from Health Canada for a generic version of Ozempic® (semaglutide injection).

This development is considered highly significant because semaglutide is one of the world’s most in-demand diabetes and weight management medicines. The approval positions OneSource and its partners among the first generic entrants into Canada’s semaglutide market, which is considered the world’s second-largest market for the product category.

The announcement also strengthens OneSource Specialty Pharma’s position as a growing global Contract Development and Manufacturing Organization (CDMO) focused on complex pharmaceutical products.

What Is Semaglutide?

Semaglutide is a widely used medicine primarily prescribed for:

• Type 2 diabetes management
• Blood sugar control
• Weight management
• Obesity treatment

The medicine gained worldwide attention because of blockbuster branded products such as:

• Ozempic®
• Wegovy®
• Rybelsus®

Demand for semaglutide-based therapies has surged globally due to rising diabetes and obesity cases.

The medicine belongs to a class called GLP-1 receptor agonists, which help regulate insulin levels, control appetite, and improve blood sugar management.

Because of its strong demand and growing market size, generic semaglutide approvals are considered major opportunities for pharmaceutical companies.

Importance Of The Canadian Approval

The approval received by Orbicular and its Canadian partner marks the second generic semaglutide approval in Canada.

This is important because Canada is one of the largest pharmaceutical markets globally for semaglutide products.

Being among the first generic entrants provides several commercial advantages:

• Early market access
• Stronger market positioning
• Better pricing opportunities
• Brand recognition in generics
• Higher revenue potential

For OneSource, the development showcases its ability to support highly regulated international markets through its manufacturing and technical capabilities.

OneSource’s Role In The Approval Process

OneSource Specialty Pharma played a critical role as the manufacturing partner in the program.

According to the company:

• Orbicular handled product development and technical program execution.
• OneSource supported manufacturing activities for the Canadian regulatory filing.

The company provided end-to-end manufacturing capabilities required for regulatory approval.

Commercial supply for the approved product will be manufactured from OneSource’s US FDA-approved flagship facility in Bengaluru.

This highlights the company’s growing importance in global pharmaceutical supply chains for complex injectable medicines.

Bengaluru Facility To Support Commercial Supply

The company confirmed that commercial production for the Canadian market will be supported through its flagship manufacturing facility in Bengaluru.

This facility is already approved by the US Food and Drug Administration (US FDA), which reflects high compliance and manufacturing standards.

US FDA-approved facilities are considered globally trusted manufacturing sites because they must follow strict quality and regulatory requirements.

The use of the Bengaluru facility demonstrates India’s increasing role as a major global pharmaceutical manufacturing hub.

Strong Momentum Across Global Markets

The Canadian approval comes shortly after OneSource supported a tentative approval in the United States for a similar semaglutide-related program.

This means the company has now contributed to approvals across multiple regulated markets, including:

• Canada
• United States
• India

The company stated that these approvals reinforce its growing capabilities in:

• Complex peptide injectables
• Drug-device combinations
• Biologics manufacturing
• Regulated market supply

The latest achievement further strengthens its global CDMO positioning.

CEO Statement On The Milestone

Neeraj Sharma, CEO and Managing Director of OneSource Specialty Pharma Limited, commented positively on the development.

According to him:

“We are pleased with these back-to-back approvals from two of our global customers in one of the most important semaglutide markets globally. This milestone reflects the strength of our CDMO platform, our compliance standards, technical expertise, and ability to scale complex drug-device-combination programs for highly regulated markets.”

The statement highlights the company’s confidence in its technical and manufacturing capabilities.

It also reflects OneSource’s strategy of becoming a preferred global CDMO partner for complex pharmaceutical products.

What Is A CDMO?

A Contract Development and Manufacturing Organization (CDMO) is a company that helps pharmaceutical firms with:

• Drug development
• Manufacturing
• Packaging
• Regulatory support
• Commercial production

Many global pharmaceutical companies outsource manufacturing to CDMOs because it reduces costs and speeds up product commercialization.

CDMOs play a very important role in the modern pharmaceutical industry, especially for complex products that require specialized expertise and infrastructure.

OneSource operates as a pure-play specialty pharma CDMO focused on advanced pharmaceutical products.

Focus On Complex Pharmaceutical Products

OneSource Specialty Pharma focuses on manufacturing and developing complex pharmaceutical products such as:

• Biologics
• Sterile injectables
• Drug-device combinations
• Peptide-based injectables
• Oral technologies
• Soft gelatin capsules

These product categories generally have higher entry barriers because they require:

• Advanced manufacturing facilities
• Regulatory expertise
• Technical knowledge
• High compliance standards

As a result, companies operating in these segments often enjoy better growth opportunities and stronger client relationships.

Growth Of The Global Semaglutide Market

The global semaglutide market has been expanding rapidly due to increasing demand for diabetes and obesity treatments.

Several factors are driving this growth:

• Rising diabetes cases worldwide
• Growing obesity concerns
• Increased awareness of weight management
• Strong clinical outcomes
• Expanding healthcare access

Global pharmaceutical companies are investing heavily in semaglutide-related products because demand continues to outpace supply in several markets.

Generic versions are expected to play a major role in improving affordability and accessibility.

India’s Growing Role In Global Pharma Manufacturing

The announcement also highlights India’s growing role in global pharmaceutical manufacturing.

Indian pharmaceutical companies are increasingly becoming trusted suppliers for highly regulated markets such as:

• United States
• Europe
• Canada
• Japan
• Australia

India’s strengths include:

• Skilled workforce
• Cost-efficient manufacturing
• Regulatory expertise
• Large-scale production capabilities
• Advanced pharma infrastructure

Companies like OneSource are helping position India as a global hub for specialty pharmaceutical manufacturing.

OneSource’s Manufacturing Infrastructure

OneSource Specialty Pharma currently operates:

• Five state-of-the-art manufacturing facilities
• Approved by multiple global regulatory authorities
• Supported by over 1,600 professionals

The company stated that its infrastructure supports development and manufacturing of highly specialized pharmaceutical products.

Strong compliance records and regulatory approvals are critical for companies supplying international pharmaceutical markets.

Importance Of Regulatory Approvals

Approvals from agencies like Health Canada and the US FDA are considered major achievements in the pharmaceutical industry.

Such approvals indicate that manufacturing facilities and products meet strict standards related to:

• Safety
• Quality
• Efficacy
• Compliance
• Manufacturing controls

For CDMO companies, regulatory credibility is essential because global pharmaceutical clients depend heavily on compliance standards.

The latest approval could help OneSource attract additional international partnerships in the future.

Drug-Device Combination Market Opportunity

OneSource also emphasized its focus on drug-device combinations.

Drug-device combinations refer to products where medicines are integrated with delivery devices, such as:

• Injectable pens
• Auto-injectors
• Smart delivery systems

Semaglutide products often involve such advanced delivery systems.

This segment is growing rapidly because patients increasingly prefer convenient and user-friendly treatment methods.

The ability to manufacture complex drug-device combinations provides a strong competitive advantage in the pharmaceutical industry.

Expansion In India Market

The company also mentioned that the Canadian approval builds upon momentum in India.

According to the company, OneSource has already been supplying semaglutide-related products for multiple brands launched by partners in India during March.

India is witnessing growing demand for diabetes and obesity treatment products due to changing lifestyles and rising healthcare awareness.

The domestic market could therefore become another major growth driver for semaglutide-based products.

Competitive Advantage Of End-To-End Manufacturing

OneSource’s integrated manufacturing approach provides several advantages.

The company offers:

• Product development support
• Manufacturing services
• Regulatory support
• Commercial supply capabilities

This end-to-end model allows pharmaceutical partners to streamline product commercialization.

For global pharma companies, working with a single integrated CDMO partner can reduce:

• Time to market
• Supply chain complexity
• Manufacturing coordination challenges

This strengthens long-term business relationships.

Investor Perspective On The Announcement

From an investor standpoint, the latest announcement demonstrates:

• Expanding global presence
• Regulatory success
• Technical capability
• Growing CDMO opportunities
• Strength in high-value pharma segments

Semaglutide-related products are currently among the fastest-growing pharmaceutical categories globally.

Participation in this market could create long-term revenue opportunities for OneSource.

Investors may also view approvals in regulated markets positively because they indicate strong compliance standards and manufacturing quality.

Pharmaceutical Industry Trends Supporting Growth

Several industry trends are currently benefiting specialty pharma CDMOs like OneSource.

Outsourcing By Global Pharma Companies

Large pharmaceutical firms increasingly outsource manufacturing to reduce costs and improve efficiency.

Rising Demand For Complex Medicines

Demand for biologics, injectables, and specialty drugs continues growing globally.

Regulatory Compliance Requirements

Highly regulated markets require trusted manufacturing partners with strong compliance records.

Expansion Of Generic Drugs

Patent expiries are creating opportunities for generic versions of high-demand medicines.

These trends support long-term growth prospects for advanced pharmaceutical CDMOs.

Risks And Industry Challenges

Despite strong opportunities, the pharmaceutical sector also faces challenges such as:

• Regulatory risks
• Product approval delays
• Pricing pressure
• Supply chain disruptions
• Competition
• Patent-related disputes

Companies operating in regulated markets must continuously maintain high compliance standards.

Failure to meet regulatory requirements can impact approvals and commercial operations.

Long-Term Outlook For OneSource Specialty Pharma

OneSource appears focused on strengthening its position as a global specialty pharma CDMO.

Its strategy includes:

• Expanding complex injectable capabilities
• Supporting global pharmaceutical partners
• Growing biologics manufacturing
• Increasing regulated market exposure
• Enhancing drug-device combination expertise

The company’s recent approvals and manufacturing partnerships indicate growing international recognition.

As global demand for advanced pharmaceutical products continues increasing, companies with strong manufacturing and compliance capabilities may benefit significantly.

Conclusion

The support provided by OneSource Specialty Pharma Limited for the second generic semaglutide approval in Canada marks a major milestone in the company’s global growth journey.

The approval positions OneSource and its partners among the first generic entrants into one of the world’s most important semaglutide markets.

By supporting manufacturing from its US FDA-approved Bengaluru facility, the company has demonstrated its capability to serve highly regulated global markets.

The development also highlights OneSource’s growing strength in:

• Complex peptide injectables
• Drug-device combinations
• Specialty pharmaceutical manufacturing
• Global CDMO partnerships

With rising worldwide demand for semaglutide products and increasing outsourcing trends in the pharmaceutical industry, OneSource appears well-positioned to expand its role as a trusted global CDMO partner.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.